Log inSign up
Scribe Therapeutics profile banner
user avatar

Scribe Therapeutics

@scribetx
CRISPR by Design™
Alameda, CA
scribetx.com
Joined April 2017
1
Following
1,632
Followers
RepliesMedia
  • Pinned
    user avatar
    Scribe Therapeutics
    @scribetx
    May 21
    Announcing our first clinical trial. Scribe has secured regulatory clearance from Australia’s @TGAgovau to initiate a first-in-human clinical study of STX-1150 for the treatment of hypercholesterolemia, a major driver of atherosclerotic cardiovascular disease (ASCVD). Details🧵
    00:00
  • user avatar
    Scribe Therapeutics
    @scribetx
    Aug 7
    𝗜𝗻𝘁𝗿𝗼𝗱𝘂𝗰𝗶𝗻𝗴 𝗦𝗰𝗿𝗶𝗯𝗲 𝗦𝘆𝗹𝗹𝗮𝗯𝘂𝘀, a new educational series exploring the science behind our mission to rewrite the story of disease through prevention. Today, most genetic medicines are designed for rare diseases. At Scribe, we're building technologies that
    GIF
  • user avatar
    Scribe Therapeutics
    @scribetx
    Jul 28
    Imagine a world where heart disease, the world’s leading cause of death, can be prevented. At Scribe, we are building custom solutions to address the full spectrum of lipid risk – all three major lipid drivers of cardiovascular disease. 🧵
    user avatar
    Nasdaq Exchange
    Nasdaq
    @NasdaqExchange
    Jul 27
    .@scribetx is engineering purpose-built CRISPR medicines to broaden access to cardioprotective genetics for us all. Look back on $SCTX’s milestone celebration becoming #NasdaqListed and delivering a new era of scalable, transformative, and preventative genetic medicines.
    00:00
  • user avatar
    Scribe Therapeutics
    @scribetx
    Jul 27
    We announced the closing of our initial public offering of 9,867,000 shares of common stock at $15 per share, along with a concurrent private placement, for combined gross proceeds of approximately $155.51 million before underwriting discounts and commissions.